BioWorld

May 16, 2006

AstraZeneca Buying CAT, Giving Valuation Of $1.3B

LONDON - AstraZeneca plc is buying Cambridge Antibody Technology (CAT) Group plc, the UK's largest biotech, in an agreed cash deal that will cost AstraZeneca £567 million, and values CAT at £702 million (US$1.3 billion). (BioWorld Today) Read More

Clinical Data Spins Off Precigen To Continue Phase III Research

Marshall Edwards Licenses Two Oncology Compounds

Congresswoman Calls For More FDA Power On Phase IV Studies

Clinic Roundup

U.S. Patent Disclosures

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Researchers hit back after colleagues removed from ADA meeting

BioWorld

Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...